Cancer immunotherapy

By T. Gajewski. Molecular Oncology, 2012

906 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

30 years of NF-κB: a blossoming of relevance to human pathobiology (2017, neutral): “[PubMed: 14523047] Couzin-Frankel J. Breakthrough of the year 2013.”
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “The evolution of immune checkpoint inhibitors as anticancer treatment options represents one of the most successful approach in cancer drug discovery in the past few years (Couzin-Frankel, 2013).”
Oncology meets immunology: the cancer-immunity cycle. (2013, background): “Conversely, PD-L1 or PD-1 inhibition may not be sufficient for optimal antitumor activity in some patients, particularly those that do not demonstrate evidence of tumor immune cell infiltration (Gajewski et al., 2011, 2013; Gajewski, 2012).”
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors (2014, background): “Other work has indicated that immune escape in these cases is mediated by immune inhibitory mechanisms that function at within the tumor microenvironment (Gajewski and Schumacher, 2013; Spranger et al., 2013).”